https://drugnews.com.tw/en/ Independent biotech and pharmaceutical intelligence from Taiwan, covering clinical data, company strategy, licensing, valuation, and capital markets. en https://drugnews.com.tw/articles/2026-07-17-revmed-ras-en.html https://drugnews.com.tw/articles/2026-07-17-revmed-ras-en.html Fri, 17 Jul 2026 01:46:13 GMT Daraxonrasib has already raised the bar with phase 3 overall-survival data. Early zoldonrasib combinations now suggest that pancreatic cancer's RAS competition is shifting from single agents to treatment ecosystems. https://drugnews.com.tw/en/guides/regulatory-milestones.html https://drugnews.com.tw/en/guides/regulatory-milestones.html Fri, 17 Jul 2026 01:00:00 GMT A practical guide to INDs, FDA designations, pivotal alignment, NDA/BLA review, PDUFA dates, advisory committees, complete response letters, and approval pathways. https://drugnews.com.tw/en/guides/bd-licensing-terms.html https://drugnews.com.tw/en/guides/bd-licensing-terms.html Fri, 17 Jul 2026 01:00:00 GMT A practical guide to biotech licensing terms: upfront cash, milestones, royalties, territory, control, development obligations, supply, termination, and risk-adjusted deal economics. https://drugnews.com.tw/en/guides/clinical-endpoints.html https://drugnews.com.tw/en/guides/clinical-endpoints.html Fri, 17 Jul 2026 01:00:00 GMT A practical guide to primary endpoints, effect size, confidence intervals, multiplicity, surrogate endpoints, and the questions that keep a positive biotech readout from being overread. https://drugnews.com.tw/articles/2026-07-16-big-pharma-ma-new-aesthetic-en.html https://drugnews.com.tw/articles/2026-07-16-big-pharma-ma-new-aesthetic-en.html Thu, 16 Jul 2026 00:00:00 GMT Vertex's roughly $10 billion deal for Crinetics captures a wider change in Big Pharma's acquisition taste: away from scale and fashionable platforms, toward niche leadership, technological step-changes and commercial visibility. https://drugnews.com.tw/articles/2026-07-15-treg-immune-tolerance-productization-en.html https://drugnews.com.tw/articles/2026-07-15-treg-immune-tolerance-productization-en.html Wed, 15 Jul 2026 00:00:00 GMT The Nobel Prize illuminated Treg biology, but commercial value will depend on whether immune tolerance can become a releasable, trackable, scalable and reimbursable product, not on an unverified first-approval headline. https://drugnews.com.tw/articles/2026-07-14-novartis-myricx-nmti-adc-en.html https://drugnews.com.tw/articles/2026-07-14-novartis-myricx-nmti-adc-en.html Tue, 14 Jul 2026 00:00:00 GMT Novartis is paying up to $1.5 billion for Myricx. The strategic prize is not merely two ADC assets, but an NMT-inhibitor payload platform that could reopen the questions of therapeutic window, resistance and platform value. https://drugnews.com.tw/articles/2026-07-13-anthropic-claude-science-ai-drug-discovery-en.html https://drugnews.com.tw/articles/2026-07-13-anthropic-claude-science-ai-drug-discovery-en.html Mon, 13 Jul 2026 00:00:00 GMT Anthropic's launch of Claude Science and its move into drug discovery show foundation-model companies shifting from research tools into real R&D workflows. AI drug discovery will ultimately be judged by experiments, clinical data and tradable assets. https://drugnews.com.tw/articles/2026-07-12-roche-divarasib-kras-generation-en.html https://drugnews.com.tw/articles/2026-07-12-roche-divarasib-kras-generation-en.html Sun, 12 Jul 2026 00:00:00 GMT Roche's divarasib beat first-generation KRAS G12C inhibitors in a head-to-head Phase III study, moving the RAS field from proving druggability to replacing earlier products with harder clinical evidence. https://drugnews.com.tw/articles/2026-07-11-fasedienol-cns-en.html https://drugnews.com.tw/articles/2026-07-11-fasedienol-cns-en.html Sat, 11 Jul 2026 01:49:00 GMT Fasedienol's PALISADE-4 miss was not simply a failed Phase 3 headline. It exposed the core CNS drug-development problem: a beautiful mechanism and a real unmet need still have to survive subjective endpoints, placebo response, patient selection, and a commercial repositioning test. https://drugnews.com.tw/articles/2026-07-10-fda-nasp-en.html https://drugnews.com.tw/articles/2026-07-10-fda-nasp-en.html Fri, 10 Jul 2026 01:49:00 GMT FDA identified no clinical efficacy or safety concerns that affected NASP's approvability. The setback centered on CMC controls and contract-manufacturing deficiencies, showing biotech investors why manufacturing credibility becomes part of asset value near launch. https://drugnews.com.tw/articles/2026-07-09-japan-biotech-ecosystem-global-gap-en.html https://drugnews.com.tw/articles/2026-07-09-japan-biotech-ecosystem-global-gap-en.html Thu, 09 Jul 2026 01:30:00 GMT Japan has strong science, major pharmaceutical companies, and a large drug market. The harder question is why that foundation has not produced more global-scale biotech startups. The answer is not scientific weakness, but an ecosystem gap across assets, talent, capital, clinical execution, and exits. https://drugnews.com.tw/articles/2026-07-08-glp1-dorzagliatin-long-term-metabolic-base-en.html https://drugnews.com.tw/articles/2026-07-08-glp1-dorzagliatin-long-term-metabolic-base-en.html Wed, 08 Jul 2026 01:10:35 GMT GLP-1 competition is moving from peak weight loss toward long-term use, tolerability, rebound control, and combination design. Dorzagliatin matters not as a GLP-1 replacement, but as a possible metabolic base for the next phase of chronic therapy. https://drugnews.com.tw/articles/2026-07-07-pfizer-seagen-3sbio-adc-pd1-vegf-en.html https://drugnews.com.tw/articles/2026-07-07-pfizer-seagen-3sbio-adc-pd1-vegf-en.html Tue, 07 Jul 2026 00:49:37 GMT After a Phase III setback for sigvotatug vedotin, Pfizer's $43 billion Seagen ADC bet is increasingly tied to whether 3SBio's PD-1/VEGF bispecific can become a new immuno-oncology combination backbone. https://drugnews.com.tw/articles/2026-07-06-universal-car-t-2026-rebound-en.html https://drugnews.com.tw/articles/2026-07-06-universal-car-t-2026-rebound-en.html Mon, 06 Jul 2026 04:26:18 GMT Off-the-shelf allogeneic CAR-T is no longer just a beautiful manufacturing story. In 2026, better clinical signals and clearer positioning are bringing the field back to the table. https://drugnews.com.tw/articles/2026-07-05-big-pharma-134b-biotech-ma-en.html https://drugnews.com.tw/articles/2026-07-05-big-pharma-134b-biotech-ma-en.html Sun, 05 Jul 2026 04:10:13 GMT In the first half of 2026, Big Pharma's biotech M&A pace has accelerated sharply. The real question is not why large drugmakers have cash, but why they are suddenly less willing to wait. https://drugnews.com.tw/articles/2026-07-04-hhs-operation-trialblazer-clinical-trials-en.html https://drugnews.com.tw/articles/2026-07-04-hhs-operation-trialblazer-clinical-trials-en.html Sat, 04 Jul 2026 00:35:00 GMT Operation TrialBlazer is not just an FDA efficiency program. It signals that the United States is treating clinical-trial speed as part of national biotech competitiveness, with direct implications for biotech valuation, financing windows, and regulatory strategy. https://drugnews.com.tw/articles/2026-07-03-revmed-biotech-en.html https://drugnews.com.tw/articles/2026-07-03-revmed-biotech-en.html Fri, 03 Jul 2026 02:30:00 GMT Revolution Medicines is choosing not to make a sale its priority. The decision reflects a broader shift: top-tier biotech companies with breakthrough assets may once again have a credible path to grow into independent biopharma companies. https://drugnews.com.tw/articles/2026-07-02-synthetic-lethality-next-parp-en.html https://drugnews.com.tw/articles/2026-07-02-synthetic-lethality-next-parp-en.html Thu, 02 Jul 2026 02:30:00 GMT PARP inhibitors turned synthetic lethality into a commercial reality. Two decades later, the industry is still asking why the next PARP-like blockbuster has been so difficult to reproduce. https://drugnews.com.tw/articles/2026-07-01-adhd-centanafadine-phase3b-en.html https://drugnews.com.tw/articles/2026-07-01-adhd-centanafadine-phase3b-en.html Wed, 01 Jul 2026 02:30:00 GMT Otsuka’s centanafadine has reported positive Phase 3b data in adults with ADHD and comorbid anxiety. The FDA has accepted the NDA and granted priority review, making the program a useful lens for how ADHD treatment is shifting from behavioral stigma toward more precise neurobiological intervention. https://drugnews.com.tw/articles/2026-06-30-gsk-nuvalent-oncology-comeback-en.html https://drugnews.com.tw/articles/2026-06-30-gsk-nuvalent-oncology-comeback-en.html Tue, 30 Jun 2026 00:43:58 GMT GSK's $10.6 billion all-cash acquisition of Nuvalent is more than a late-stage lung-cancer pipeline deal. It is a strategic attempt to rebuild oncology, buy time before major revenue pressure, and regain a seat at the precision-oncology table. https://drugnews.com.tw/articles/2026-06-29-biotech-ipo-en.html https://drugnews.com.tw/articles/2026-06-29-biotech-ipo-en.html Mon, 29 Jun 2026 05:50:47 GMT Parabilis Medicines' record-setting US biotech IPO is not a sign that speculative biotech is back. It shows that investors are willing to fund high-risk innovation when the platform, clinical asset, external validation, and capital-market window all line up. https://drugnews.com.tw/articles/2026-06-28-fda-regulatory-shift-biotech-rebound-en.html https://drugnews.com.tw/articles/2026-06-28-fda-regulatory-shift-biotech-rebound-en.html Sun, 28 Jun 2026 00:50:00 GMT Biotech’s recent rebound is not only a risk-on trade. FDA review signals, rare-disease flexibility, mRNA vaccine momentum, and renewed pharma M&A are changing how investors price clinical-stage assets. https://drugnews.com.tw/articles/2026-06-27-pancreatic-cancer-ras-prmt5-mat2a-combination-en.html https://drugnews.com.tw/articles/2026-06-27-pancreatic-cancer-ras-prmt5-mat2a-combination-en.html Sat, 27 Jun 2026 02:30:00 GMT Pancreatic cancer is moving into a new phase of precision combination therapy, as RAS inhibition meets MTAP-selective PRMT5 and MAT2A strategies. https://drugnews.com.tw/articles/2026-06-26-tirzepatide-autoimmune-immunometabolism-en.html https://drugnews.com.tw/articles/2026-06-26-tirzepatide-autoimmune-immunometabolism-en.html Fri, 26 Jun 2026 02:30:00 GMT Lilly is testing whether tirzepatide can move beyond weight loss and become part of an immunometabolism strategy for chronic immune-inflammatory diseases. https://drugnews.com.tw/articles/2026-06-25-protect-pet-medical-roche-platform-en.html https://drugnews.com.tw/articles/2026-06-25-protect-pet-medical-roche-platform-en.html Thu, 25 Jun 2026 00:30:00 GMT As companion animals age and owners become more willing to pay for serious-disease care, the next major question in pet medicine is whether a platform company can connect drugs, diagnostics, veterinary clinics, regulation, manufacturing, channels, and data into one defensible system. https://drugnews.com.tw/articles/2026-06-24-ai-zasocitinib-sotyktu-en.html https://drugnews.com.tw/articles/2026-06-24-ai-zasocitinib-sotyktu-en.html Wed, 24 Jun 2026 00:13:00 GMT Takeda's zasocitinib beat Sotyktu in a head-to-head Phase 3 psoriasis study, turning AI-enabled drug design into a real commercial test. https://drugnews.com.tw/articles/2026-06-22-obesity-drug-third-place-competition-en.html https://drugnews.com.tw/articles/2026-06-22-obesity-drug-third-place-competition-en.html Mon, 22 Jun 2026 00:49:01 GMT Lilly and Novo Nordisk dominate the first phase of the obesity-drug market. The next investment question is who can become the third major player by solving the problems GLP-1 leaders have not fully solved. https://drugnews.com.tw/articles/2026-06-21-merck-pd1-vegf-mk2010-keytruda-en.html https://drugnews.com.tw/articles/2026-06-21-merck-pd1-vegf-mk2010-keytruda-en.html Sun, 21 Jun 2026 00:00:00 GMT Merck's more serious positioning of MK-2010 suggests that PD-1/VEGF bispecifics are moving from a watch item to a strategic option in the post-Keytruda oncology landscape. https://drugnews.com.tw/articles/2026-06-20-enlivex-rain-token-biotech-treasury-en.html https://drugnews.com.tw/articles/2026-06-20-enlivex-rain-token-biotech-treasury-en.html Sat, 20 Jun 2026 00:00:00 GMT Enlivex's paper gain from RAIN tokens shows how fragile biotech business models can create unusual treasury stories when operating revenue is absent and capital markets are difficult. https://drugnews.com.tw/articles/2026-06-19-gsk-nuvalent-lung-cancer-resistance-brain-metastasis-en.html https://drugnews.com.tw/articles/2026-06-19-gsk-nuvalent-lung-cancer-resistance-brain-metastasis-en.html Fri, 19 Jun 2026 00:00:00 GMT GSK is not merely buying three lung-cancer pipelines. It is buying a next-generation precision-oncology strategy around resistance, CNS activity, and cleaner kinase inhibition. https://drugnews.com.tw/articles/2026-06-17-glp1-head-to-head-ecnoglutide-wegovy-en.html https://drugnews.com.tw/articles/2026-06-17-glp1-head-to-head-ecnoglutide-wegovy-en.html Wed, 17 Jun 2026 01:30:00 GMT Ecnoglutide's head-to-head weight-loss data versus semaglutide are interesting, but the GLP-1 race will be decided by long-term outcomes, tolerability, labels, supply, and global evidence. https://drugnews.com.tw/articles/2026-06-16-lilly-vaccine-acquisitions-prevention-medicine-en.html https://drugnews.com.tw/articles/2026-06-16-lilly-vaccine-acquisitions-prevention-medicine-en.html Tue, 16 Jun 2026 03:00:00 GMT Lilly's vaccine acquisitions show that the company is using obesity-drug cash flow to widen its long-term disease-prevention and immunology strategy. https://drugnews.com.tw/articles/2026-06-15-2026-asco-car-t-en.html https://drugnews.com.tw/articles/2026-06-15-2026-asco-car-t-en.html Mon, 15 Jun 2026 02:35:00 GMT ASCO 2026 showed that oncology is moving from single-mechanism breakthroughs toward platform combinations across RAS targeting, ADCs, PD-1/VEGF bispecifics, and in vivo CAR-T. https://drugnews.com.tw/articles/2026-06-14-revolution-medicines-en.html https://drugnews.com.tw/articles/2026-06-14-revolution-medicines-en.html Sun, 14 Jun 2026 00:54:00 GMT Revolution Medicines shows why next-generation biotech companies need to convert clinical momentum into capital momentum if they want to finish expensive global drug-development races. https://drugnews.com.tw/articles/2026-06-13-anhorn-ai-drug-development-en.html https://drugnews.com.tw/articles/2026-06-13-anhorn-ai-drug-development-en.html Sat, 13 Jun 2026 07:20:00 GMT AI drug development is moving from molecular generation to clinical survival. AnHorn Medicines shows how AI+PROTAC, experimental feedback, and human translation may form a Taiwan-born clinical-asset engine. https://drugnews.com.tw/articles/2026-06-12-ai-drug-discovery-pipeline-20260612-en.html https://drugnews.com.tw/articles/2026-06-12-ai-drug-discovery-pipeline-20260612-en.html Fri, 12 Jun 2026 02:30:00 GMT AI drug discovery has moved beyond the concept stage and into clinical validation. This article reviews Zasocitinib, GB-0895, Zovegalisib, and REC-4881 to examine how different AI strategies are being converted into real drug assets. https://drugnews.com.tw/articles/2026-06-11-glp1-biotech-capital-reshuffle-en.html https://drugnews.com.tw/articles/2026-06-11-glp1-biotech-capital-reshuffle-en.html Thu, 11 Jun 2026 00:00:01 GMT GLP-1 is no longer only a weight-loss topic. It is redirecting biotech capital, BD urgency, manufacturing attention, and valuation imagination across global pharma. https://drugnews.com.tw/articles/2026-06-10-sinphar-cx5461-ras-pancreatic-cancer-en.html https://drugnews.com.tw/articles/2026-06-10-sinphar-cx5461-ras-pancreatic-cancer-en.html Wed, 10 Jun 2026 02:45:00 GMT Daraxonrasib opens a new pancreatic-cancer window, but the next value question is resistance management. Senhwa's CX-5461 matters if it can become a rational combination partner. https://drugnews.com.tw/articles/2026-06-10-biotech-ir-capital-market-story-en.html https://drugnews.com.tw/articles/2026-06-10-biotech-ir-capital-market-story-en.html Wed, 10 Jun 2026 02:30:00 GMT Biotech IR is not cosmetic storytelling. Good IR turns clinical, CMC, regulatory, commercial, and financing milestones into a capital-market narrative that investors can actually track. https://drugnews.com.tw/articles/2026-06-09-curium-lantheus-radiopharma-acquisition-en.html https://drugnews.com.tw/articles/2026-06-09-curium-lantheus-radiopharma-acquisition-en.html Tue, 09 Jun 2026 02:30:00 GMT Curium's rumored interest in Lantheus is best read as a bid for nuclear-medicine infrastructure: isotope access, hospital channels, imaging workflow, and radiopharma commercialization depth. https://drugnews.com.tw/articles/2026-06-08-cart-autoimmune-new-era-en.html https://drugnews.com.tw/articles/2026-06-08-cart-autoimmune-new-era-en.html Mon, 08 Jun 2026 02:30:00 GMT CAR-T's move from blood cancer into autoimmune disease could redefine cell therapy, but the value depends on whether deep immune reset can justify manufacturing complexity, safety risk, and cost. https://drugnews.com.tw/articles/2026-06-07-pharma-ai-capability-future-en.html https://drugnews.com.tw/articles/2026-06-07-pharma-ai-capability-future-en.html Sun, 07 Jun 2026 02:30:00 GMT AI is becoming a core operating capability for pharma, but its value comes from improving discovery, translation, trial design, and portfolio decisions rather than from marketing language alone. https://drugnews.com.tw/articles/2026-06-06-old-targets-differentiation-strategy-en.html https://drugnews.com.tw/articles/2026-06-06-old-targets-differentiation-strategy-en.html Sat, 06 Jun 2026 02:30:00 GMT Crowded drug targets can still create value when companies differentiate through patient selection, formulation, route of administration, clinical design, pricing, or commercial channel strategy. https://drugnews.com.tw/articles/2026-06-05-topical-jak-inhibitor-skin-delivery-en.html https://drugnews.com.tw/articles/2026-06-05-topical-jak-inhibitor-skin-delivery-en.html Fri, 05 Jun 2026 02:30:00 GMT Topical JAK drugs are not won by target biology alone. The real value lies in skin delivery, local exposure, systemic safety, indication choice, and whether the product can fit daily dermatology practice. https://drugnews.com.tw/articles/2026-06-04-retatrutide-obesity-surgery-level-weight-loss-en.html https://drugnews.com.tw/articles/2026-06-04-retatrutide-obesity-surgery-level-weight-loss-en.html Thu, 04 Jun 2026 02:30:00 GMT Retatrutide pushes obesity-drug efficacy toward surgery-level territory, but the real competitive battle will be durability, tolerability, body composition, comorbidity benefit, and access. https://drugnews.com.tw/articles/2026-06-03-aatd-new-therapy-rna-gene-editing-en.html https://drugnews.com.tw/articles/2026-06-03-aatd-new-therapy-rna-gene-editing-en.html Wed, 03 Jun 2026 02:30:00 GMT AATD is entering a new treatment cycle after decades of limited options, with RNA and gene-based approaches trying to move the field beyond symptom control and protein replacement. https://drugnews.com.tw/articles/2026-06-02-biogen-alzheimers-tau-biib080-strategy-en.html https://drugnews.com.tw/articles/2026-06-02-biogen-alzheimers-tau-biib080-strategy-en.html Tue, 02 Jun 2026 02:30:00 GMT Biogen's BIIB080 tau program reflects a broader Alzheimer's reset: the field is no longer only asking whether amyloid matters, but whether tau biology can produce measurable disease-modifying benefit. https://drugnews.com.tw/articles/2026-06-01-pluvicto-radioligand-therapy-growth-en.html https://drugnews.com.tw/articles/2026-06-01-pluvicto-radioligand-therapy-growth-en.html Mon, 01 Jun 2026 02:30:00 GMT Pluvicto's rapid growth shows radioligand therapy moving from specialist science into a real commercial infrastructure story, where isotope supply, hospital workflow, and patient selection become strategic assets. https://drugnews.com.tw/articles/2026-05-31-tavneos-safety-data-integrity-crisis-en.html https://drugnews.com.tw/articles/2026-05-31-tavneos-safety-data-integrity-crisis-en.html Sun, 31 May 2026 02:30:00 GMT A Drugnews English brief on The Tavneos Crisis: Death Reports, Data-Integrity Questions, and an Amgen Rare-Disease Star at the Edge of Withdrawal, focusing on regulatory risk, clinical evidence, company strategy, business development, and biotech capital-market implications. https://drugnews.com.tw/articles/2026-05-30-drug-combination-efficacy-doubling-en.html https://drugnews.com.tw/articles/2026-05-30-drug-combination-efficacy-doubling-en.html Sat, 30 May 2026 02:30:00 GMT A Drugnews English brief on The Best Partner for a Drug King? When Combination Therapy Doubles Efficacy, focusing on company strategy, clinical evidence, company strategy, business development, and biotech capital-market implications. https://drugnews.com.tw/articles/2026-05-29-next-generation-obesity-therapy-directions-en.html https://drugnews.com.tw/articles/2026-05-29-next-generation-obesity-therapy-directions-en.html Fri, 29 May 2026 02:30:00 GMT A Drugnews English brief on Weight-Loss Drugs Are No Longer Only About Body Weight: Where Next-Generation Therapies Are Aiming, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications. https://drugnews.com.tw/articles/2026-05-28-biotech-investment-judgment-system-en.html https://drugnews.com.tw/articles/2026-05-28-biotech-investment-judgment-system-en.html Thu, 28 May 2026 02:30:00 GMT A Drugnews English brief on Biotech Investing Needs a Judgment System, Not More News, focusing on business development, clinical evidence, company strategy, business development, and biotech capital-market implications. https://drugnews.com.tw/articles/2026-05-27-taiwan-biotech-valuation-framework-en.html https://drugnews.com.tw/articles/2026-05-27-taiwan-biotech-valuation-framework-en.html Wed, 27 May 2026 02:30:00 GMT A Drugnews English brief on The First Step in Valuing Taiwanese Biotech: Stop Forcing Every Company Into the Same P/E Ratio, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications. https://drugnews.com.tw/articles/2026-05-27-generic-pharma-transformation-anxiety-en.html https://drugnews.com.tw/articles/2026-05-27-generic-pharma-transformation-anxiety-en.html Wed, 27 May 2026 02:30:00 GMT A Drugnews English brief on Sun Pharma, Teva, and the Transformation Anxiety of Global Generic Drugmakers, focusing on big pharma, clinical evidence, company strategy, business development, and biotech capital-market implications. https://drugnews.com.tw/articles/2026-05-26-weight-loss-side-effect-new-track-en.html https://drugnews.com.tw/articles/2026-05-26-weight-loss-side-effect-new-track-en.html Tue, 26 May 2026 02:30:00 GMT A Drugnews English brief on A New Weight-Loss Drug Side Effect Accidentally Opens a New Therapeutic Track, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications. https://drugnews.com.tw/articles/2026-05-25-asthma-new-drug-immune-targets-en.html https://drugnews.com.tw/articles/2026-05-25-asthma-new-drug-immune-targets-en.html Mon, 25 May 2026 02:30:00 GMT A Drugnews English brief on Asthma Drugs Are Shifting Gears: From Triple Inhalers to Upstream Immune Targets, focusing on immunology, clinical evidence, company strategy, business development, and biotech capital-market implications. https://drugnews.com.tw/articles/2026-05-24-ox2r-cns-narcolepsy-opportunity-en.html https://drugnews.com.tw/articles/2026-05-24-ox2r-cns-narcolepsy-opportunity-en.html Sun, 24 May 2026 02:30:00 GMT A Drugnews English brief on Why OX2R Is Heating Up: From Narcolepsy to the Next CNS Drug Opportunity, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications. https://drugnews.com.tw/articles/2026-05-23-global-biotech-obesity-megatrend-en.html https://drugnews.com.tw/articles/2026-05-23-global-biotech-obesity-megatrend-en.html Sat, 23 May 2026 02:30:00 GMT A Drugnews English brief on The Global Biotech Wave: Understanding the Main Phase and Scientific Pricing of the Five-Trillion Weight-Loss Market, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications. https://drugnews.com.tw/articles/2026-05-22-mid-size-biotech-blockbuster-cashflow-en.html https://drugnews.com.tw/articles/2026-05-22-mid-size-biotech-blockbuster-cashflow-en.html Fri, 22 May 2026 02:30:00 GMT A Drugnews English brief on How Mid-Sized Biotechs Are Turning Blockbuster Drugs From Dreams Into Cash Flow, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications. https://drugnews.com.tw/articles/2026-05-21-ai-semiconductor-biotech-capital-neglect-en.html https://drugnews.com.tw/articles/2026-05-21-ai-semiconductor-biotech-capital-neglect-en.html Thu, 21 May 2026 02:30:00 GMT A Drugnews English brief on How AI Semiconductors Have Hidden the Biotech Opportunity in Plain Sight, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications. https://drugnews.com.tw/articles/2026-05-20-ai-drug-discovery-google-funding-en.html https://drugnews.com.tw/articles/2026-05-20-ai-drug-discovery-google-funding-en.html Wed, 20 May 2026 02:30:00 GMT A Drugnews English brief on A Record AI Drug-Discovery Financing: Why a Google-Backed Company Raised US$2.1 Billion, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications. https://drugnews.com.tw/articles/2026-05-19-gilead-hiv-yeztugo-prep-growth-en.html https://drugnews.com.tw/articles/2026-05-19-gilead-hiv-yeztugo-prep-growth-en.html Tue, 19 May 2026 02:30:00 GMT A Drugnews English brief on HIV Drugs Are Still Highly Profitable: What Gilead's Earnings Reveal, focusing on car-t, clinical evidence, company strategy, business development, and biotech capital-market implications. https://drugnews.com.tw/articles/2026-05-18-pfizer-vepdegestrant-strategy-mistake-en.html https://drugnews.com.tw/articles/2026-05-18-pfizer-vepdegestrant-strategy-mistake-en.html Mon, 18 May 2026 02:30:00 GMT A Drugnews English brief on Where Pfizer Misjudged the Vepdegestrant Strategy, focusing on targeted therapy, clinical evidence, company strategy, business development, and biotech capital-market implications. https://drugnews.com.tw/articles/2026-05-17-jnj-auto-car-t-commercial-challenge-en.html https://drugnews.com.tw/articles/2026-05-17-jnj-auto-car-t-commercial-challenge-en.html Sun, 17 May 2026 02:30:00 GMT A Drugnews English brief on Johnson & Johnson Cuts Two Autologous Lymphoma CAR-T Programs, focusing on car-t, clinical evidence, company strategy, business development, and biotech capital-market implications. https://drugnews.com.tw/articles/2026-05-17-daiichi-sankyo-adc-capacity-lesson-en.html https://drugnews.com.tw/articles/2026-05-17-daiichi-sankyo-adc-capacity-lesson-en.html Sun, 17 May 2026 02:30:00 GMT A Drugnews English brief on Daiichi Sankyo's Most Expensive Lesson: How an ADC Capacity Bet Can Backfire After a Blockbuster, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications. https://drugnews.com.tw/articles/2026-05-16-fda-commissioner-resignation-regulatory-risk-en.html https://drugnews.com.tw/articles/2026-05-16-fda-commissioner-resignation-regulatory-risk-en.html Sat, 16 May 2026 02:30:00 GMT A Drugnews English brief on The FDA Commissioner's Exit: Why the World's Most Important Drug Referee Is Becoming Less Predictable, focusing on regulatory risk, clinical evidence, company strategy, business development, and biotech capital-market implications. https://drugnews.com.tw/articles/2026-05-15-antidepressant-new-drugs-pipeline-en.html https://drugnews.com.tw/articles/2026-05-15-antidepressant-new-drugs-pipeline-en.html Fri, 15 May 2026 02:30:00 GMT A Drugnews English brief on A Complete Map of the New Antidepressant Drug Pipeline, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications. https://drugnews.com.tw/articles/2026-05-14-pharmaessentia-besremi-mpn-valuation-en.html https://drugnews.com.tw/articles/2026-05-14-pharmaessentia-besremi-mpn-valuation-en.html Thu, 14 May 2026 02:30:00 GMT A Drugnews English brief on How PharmaEssentia's Besremi Opens a Larger Valuation Imagination, focusing on targeted therapy, clinical evidence, company strategy, business development, and biotech capital-market implications. https://drugnews.com.tw/articles/2026-05-13-neuroinflammation-cns-drug-comeback-en.html https://drugnews.com.tw/articles/2026-05-13-neuroinflammation-cns-drug-comeback-en.html Wed, 13 May 2026 02:30:00 GMT A Drugnews English brief on Could Neuroinflammation Bring CNS Drug Development Back?, focusing on cns, clinical evidence, company strategy, business development, and biotech capital-market implications. https://drugnews.com.tw/articles/2026-05-12-jnj-autoimmune-twins-stelara-transition-en.html https://drugnews.com.tw/articles/2026-05-12-jnj-autoimmune-twins-stelara-transition-en.html Tue, 12 May 2026 02:30:00 GMT A Drugnews English brief on The Autoimmune Twins That Could Save Johnson & Johnson, focusing on car-t, clinical evidence, company strategy, business development, and biotech capital-market implications. https://drugnews.com.tw/articles/2026-05-11-dac-adc-protac-next-targeted-therapy-en.html https://drugnews.com.tw/articles/2026-05-11-dac-adc-protac-next-targeted-therapy-en.html Mon, 11 May 2026 02:30:00 GMT A Drugnews English brief on Could DAC Become the Next Breakout Format in Targeted Therapy?, focusing on targeted therapy, clinical evidence, company strategy, business development, and biotech capital-market implications. https://drugnews.com.tw/articles/2026-05-10-glp1-medicare-policy-delay-en.html https://drugnews.com.tw/articles/2026-05-10-glp1-medicare-policy-delay-en.html Sun, 10 May 2026 02:30:00 GMT A Drugnews English brief on Trump Delays the Policy Signal: Did Weight-Loss Drugs Cut Prices for Nothing?, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications. https://drugnews.com.tw/articles/2026-05-09-clinical-trial-fraud-fda-withdrawal-en.html https://drugnews.com.tw/articles/2026-05-09-clinical-trial-fraud-fda-withdrawal-en.html Sat, 09 May 2026 02:30:00 GMT A Drugnews English brief on Clinical-Trial Fraud and an FDA Withdrawal Storm, focusing on regulatory risk, clinical evidence, company strategy, business development, and biotech capital-market implications. https://drugnews.com.tw/articles/2026-05-08-lilly-tirzepatide-glp1-growth-en.html https://drugnews.com.tw/articles/2026-05-08-lilly-tirzepatide-glp1-growth-en.html Fri, 08 May 2026 02:30:00 GMT A Drugnews English brief on Weight-Loss Drugs Are Still Too Strong: Lilly's Mounjaro Keeps Printing Money, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications. https://drugnews.com.tw/articles/2026-05-07-pan-ras-patent-safety-war-en.html https://drugnews.com.tw/articles/2026-05-07-pan-ras-patent-safety-war-en.html Thu, 07 May 2026 02:30:00 GMT A Drugnews English brief on The Shadow Behind the Next Century-Defining Drug, focusing on car-t, clinical evidence, company strategy, business development, and biotech capital-market implications. https://drugnews.com.tw/articles/2026-05-06-taipei-biotech-npv-workshop-en.html https://drugnews.com.tw/articles/2026-05-06-taipei-biotech-npv-workshop-en.html Wed, 06 May 2026 02:30:00 GMT A Drugnews English brief on Free Taipei Workshop: Using an NPV Framework to Identify Biotech Re-Rating Points, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications. https://drugnews.com.tw/articles/2026-05-05-pharma-pipeline-bd-attraction-en.html https://drugnews.com.tw/articles/2026-05-05-pharma-pipeline-bd-attraction-en.html Tue, 05 May 2026 02:30:00 GMT A Drugnews English brief on What Makes a Pipeline Attractive to Big Pharma?, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications. https://drugnews.com.tw/articles/2026-05-04-hair-growth-drug-breakthrough-en.html https://drugnews.com.tw/articles/2026-05-04-hair-growth-drug-breakthrough-en.html Mon, 04 May 2026 02:30:00 GMT A Drugnews English brief on The Hair-Growth Drug That Jumped 47%: Why It Could Rewrite Three Decades of Hair-Loss Treatment, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications. https://drugnews.com.tw/articles/2026-05-03-in-vivo-cart-kelonia-lilly-en.html https://drugnews.com.tw/articles/2026-05-03-in-vivo-cart-kelonia-lilly-en.html Sun, 03 May 2026 02:30:00 GMT A Drugnews English brief on In Vivo CAR-T: Bubble or the Most Expensive Ticket to Next-Generation Cell Therapy?, focusing on car-t, clinical evidence, company strategy, business development, and biotech capital-market implications. https://drugnews.com.tw/articles/2026-05-02-sun-pharma-organon-acquisition-en.html https://drugnews.com.tw/articles/2026-05-02-sun-pharma-organon-acquisition-en.html Sat, 02 May 2026 02:30:00 GMT A Drugnews English brief on The Ambition of an Indian Pharma Giant: Acquiring a US Drugmaker, focusing on big pharma, clinical evidence, company strategy, business development, and biotech capital-market implications. https://drugnews.com.tw/articles/2026-05-01-alzheimers-amyloid-hypothesis-collapse-en.html https://drugnews.com.tw/articles/2026-05-01-alzheimers-amyloid-hypothesis-collapse-en.html Fri, 01 May 2026 02:30:00 GMT A Drugnews English brief on Is the 20-Year Amyloid Hypothesis in Alzheimer's Disease Starting to Collapse?, focusing on cns, clinical evidence, company strategy, business development, and biotech capital-market implications. https://drugnews.com.tw/articles/2026-04-30-amazon-ai-nvidia-en.html https://drugnews.com.tw/articles/2026-04-30-amazon-ai-nvidia-en.html Thu, 30 Apr 2026 02:30:00 GMT A Drugnews English brief on Amazon Enters AI Drug Discovery and Challenges Nvidia's Pharma Ambition, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications. https://drugnews.com.tw/articles/2026-04-29-dcard-261388300-en.html https://drugnews.com.tw/articles/2026-04-29-dcard-261388300-en.html Wed, 29 Apr 2026 02:30:00 GMT A Drugnews English brief on A Clear Read on Lilly's Current M&A Logic, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications. https://drugnews.com.tw/articles/2026-04-28-dcard-261381952-en.html https://drugnews.com.tw/articles/2026-04-28-dcard-261381952-en.html Tue, 28 Apr 2026 02:30:00 GMT A Drugnews English brief on When a Gray-Market Industry Gets a Seat at the Table, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications. https://drugnews.com.tw/articles/2026-04-27-car-t-en.html https://drugnews.com.tw/articles/2026-04-27-car-t-en.html Mon, 27 Apr 2026 02:30:00 GMT A Drugnews English brief on Goodbye Autologous CAR-T: Why Taiwan's Cell-Therapy Bubble Also Needs to Break, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications. https://drugnews.com.tw/articles/2026-04-26-dcard-261370593-en.html https://drugnews.com.tw/articles/2026-04-26-dcard-261370593-en.html Sun, 26 Apr 2026 02:30:00 GMT A Drugnews English brief on The Healthcare-Giant Spin-Off Wave, focusing on business development, clinical evidence, company strategy, business development, and biotech capital-market implications. https://drugnews.com.tw/articles/2026-04-25-biotech-5-en.html https://drugnews.com.tw/articles/2026-04-25-biotech-5-en.html Sat, 25 Apr 2026 02:30:00 GMT A Drugnews English brief on Why Platform Biotechs Can Generate Five Times More Licensing Revenue, focusing on business development, clinical evidence, company strategy, business development, and biotech capital-market implications. https://drugnews.com.tw/articles/2026-04-24-dcard-261359193-en.html https://drugnews.com.tw/articles/2026-04-24-dcard-261359193-en.html Fri, 24 Apr 2026 02:30:00 GMT A Drugnews English brief on Investors Should Pay Attention: Drug Delivery Is a Blue Ocean, focusing on business development, clinical evidence, company strategy, business development, and biotech capital-market implications. https://drugnews.com.tw/articles/2026-04-23-dcard-261352566-en.html https://drugnews.com.tw/articles/2026-04-23-dcard-261352566-en.html Thu, 23 Apr 2026 02:30:00 GMT A Drugnews English brief on Do COPD Patients Finally Have Another New Drug Option?, focusing on business development, clinical evidence, company strategy, business development, and biotech capital-market implications. https://drugnews.com.tw/articles/2026-04-22-ai-en.html https://drugnews.com.tw/articles/2026-04-22-ai-en.html Wed, 22 Apr 2026 02:30:00 GMT A Drugnews English brief on The Three AI Giants Battling Inside Medicine, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications. https://drugnews.com.tw/articles/2026-04-21-dcard-261339270-en.html https://drugnews.com.tw/articles/2026-04-21-dcard-261339270-en.html Tue, 21 Apr 2026 02:30:00 GMT A Drugnews English brief on Did Lilly's Oral Drug Ignite the Market?, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications. https://drugnews.com.tw/articles/2026-04-20-dcard-261332702-en.html https://drugnews.com.tw/articles/2026-04-20-dcard-261332702-en.html Mon, 20 Apr 2026 02:30:00 GMT A Drugnews English brief on A Historic Moment: The Next Century-Defining Drug Has Arrived, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications. https://drugnews.com.tw/articles/2026-04-19-neuralink-10-en.html https://drugnews.com.tw/articles/2026-04-19-neuralink-10-en.html Sun, 19 Apr 2026 02:30:00 GMT A Drugnews English brief on Neuralink and the Next Trillion-Dollar Race: Ten Brain-Computer Interface Companies to Know, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications. https://drugnews.com.tw/articles/2026-04-18-biotech-ai-en.html https://drugnews.com.tw/articles/2026-04-18-biotech-ai-en.html Sat, 18 Apr 2026 02:30:00 GMT A Drugnews English brief on Could This Taiwanese Biotech Capture the Entire AI Infrastructure Dividend?, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications. https://drugnews.com.tw/articles/2026-04-17-dcard-261315054-en.html https://drugnews.com.tw/articles/2026-04-17-dcard-261315054-en.html Fri, 17 Apr 2026 02:30:00 GMT A Drugnews English brief on The Valley of Death in Innovative Drug Development, focusing on business development, clinical evidence, company strategy, business development, and biotech capital-market implications. https://drugnews.com.tw/articles/2026-04-16-2026-q2-en.html https://drugnews.com.tw/articles/2026-04-16-2026-q2-en.html Thu, 16 Apr 2026 02:30:00 GMT A Drugnews English brief on The 2026 Q2 Drug Catalysts Biotech Readers Need to Know, focusing on immunology, clinical evidence, company strategy, business development, and biotech capital-market implications. https://drugnews.com.tw/articles/2026-04-15-biotech-en.html https://drugnews.com.tw/articles/2026-04-15-biotech-en.html Wed, 15 Apr 2026 02:30:00 GMT A Drugnews English brief on The Fall of Two Star Biotechs, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications. https://drugnews.com.tw/articles/2026-04-14-dcard-261295358-en.html https://drugnews.com.tw/articles/2026-04-14-dcard-261295358-en.html Tue, 14 Apr 2026 02:30:00 GMT A Drugnews English brief on Investors Should Pay Attention to the Autoimmune Mega-Drug Race, focusing on business development, clinical evidence, company strategy, business development, and biotech capital-market implications. https://drugnews.com.tw/articles/2026-04-13-78-en.html https://drugnews.com.tw/articles/2026-04-13-78-en.html Mon, 13 Apr 2026 02:30:00 GMT A Drugnews English brief on The King of Weight-Loss Drugs: Did US$7.8 Billion Buy the Next Era of Metabolic Medicine?, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications. https://drugnews.com.tw/articles/2026-04-12-dcard-261282303-en.html https://drugnews.com.tw/articles/2026-04-12-dcard-261282303-en.html Sun, 12 Apr 2026 02:30:00 GMT A Drugnews English brief on Idiopathic Pulmonary Fibrosis Is Entering an Acceleration Phase, focusing on immunology, clinical evidence, company strategy, business development, and biotech capital-market implications. https://drugnews.com.tw/articles/2026-04-11-dcard-261276232-en.html https://drugnews.com.tw/articles/2026-04-11-dcard-261276232-en.html Sat, 11 Apr 2026 02:30:00 GMT A Drugnews English brief on Why Did the Market Like This Company More After a Clinical Failure?, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications. https://drugnews.com.tw/articles/2026-04-10-dcard-261269760-en.html https://drugnews.com.tw/articles/2026-04-10-dcard-261269760-en.html Fri, 10 Apr 2026 02:30:00 GMT A Drugnews English brief on When Should a Company Decisively Abandon a Clinical Trial?, focusing on business development, clinical evidence, company strategy, business development, and biotech capital-market implications. https://drugnews.com.tw/articles/2026-04-09-dcard-261263509-en.html https://drugnews.com.tw/articles/2026-04-09-dcard-261263509-en.html Thu, 09 Apr 2026 02:30:00 GMT A Drugnews English brief on A New Drug Finally Arrives for This Group of Rare-Disease Patients, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications. https://drugnews.com.tw/articles/2026-04-08-abivax-14-en.html https://drugnews.com.tw/articles/2026-04-08-abivax-14-en.html Wed, 08 Apr 2026 02:30:00 GMT A Drugnews English brief on The Abivax Story: How a European Biotech Became a 14-Fold Market Myth, focusing on business development, clinical evidence, company strategy, business development, and biotech capital-market implications. https://drugnews.com.tw/articles/2026-04-07-cdc-en.html https://drugnews.com.tw/articles/2026-04-07-cdc-en.html Tue, 07 Apr 2026 02:30:00 GMT A Drugnews English brief on While the US CDC Was Still Looking for a Director, focusing on regulatory risk, clinical evidence, company strategy, business development, and biotech capital-market implications. https://drugnews.com.tw/articles/2026-04-06-420-en.html https://drugnews.com.tw/articles/2026-04-06-420-en.html Mon, 06 Apr 2026 02:30:00 GMT A Drugnews English brief on The Cut-Rate Weight-Loss Injection Has Arrived: What a NT$420 Monthly Price Really Means, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications. https://drugnews.com.tw/articles/2026-04-05-dcard-261238352-en.html https://drugnews.com.tw/articles/2026-04-05-dcard-261238352-en.html Sun, 05 Apr 2026 02:30:00 GMT A Drugnews English brief on How Far Are We From a Real Anti-Aging Drug?, focusing on clinical development, clinical evidence, company strategy, business development, and biotech capital-market implications. https://drugnews.com.tw/articles/2026-04-04-dcard-261232633-en.html https://drugnews.com.tw/articles/2026-04-04-dcard-261232633-en.html Sat, 04 Apr 2026 02:30:00 GMT A Drugnews English brief on Did Weight-Loss Injections Backfire and Trigger Pancreatitis Risk?, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications. https://drugnews.com.tw/articles/2026-04-03-dcard-261227197-en.html https://drugnews.com.tw/articles/2026-04-03-dcard-261227197-en.html Fri, 03 Apr 2026 02:30:00 GMT A Drugnews English brief on After GLP-1 and Mounjaro, What Is Happening in Weight-Loss Drug R&D?, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications. https://drugnews.com.tw/articles/2026-04-02-dcard-261221419-en.html https://drugnews.com.tw/articles/2026-04-02-dcard-261221419-en.html Thu, 02 Apr 2026 02:30:00 GMT A Drugnews English brief on Can Merck Build Another Oncology Empire?, focusing on big pharma, clinical evidence, company strategy, business development, and biotech capital-market implications. https://drugnews.com.tw/articles/2026-04-01-dcard-261215001-en.html https://drugnews.com.tw/articles/2026-04-01-dcard-261215001-en.html Wed, 01 Apr 2026 02:30:00 GMT A Drugnews English brief on Innovent's Globalization Train: Did Taiwan's Forward Therapeutics Get On Board?, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.